Clinical Trials in San Diego

Showing 6301-6320 of 14,679 trials

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

NCT02242760

This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.

Acne Vulgaris

Novan, Inc.213 participantsStarted Nov 2014

Hot Springs, Arkansas, United States • Encinitas, California, United States • San Diego, California, United States +17 more locations

COMPLETEDPhase 3< 1 mile

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

NCT04178967

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.

Atopic Dermatitis

Eli Lilly and Company445 participantsStarted Oct 2019

Scottsdale, Arizona, United States • Rogers, Arkansas, United States • Bakersfield, California, United States +86 more locations

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

Find Trials by Condition in San Diego

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Impact of Prevnar 13 on Ear Infections in Children

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Dimethyl Fumarate (DMF) Observational Study

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Study of Diroximel Fumarate in the Real-World Setting

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors